publication date: Jul. 1, 2016
Issue 26 - Jul. 1, 2016
  • News Analysis

    Biden’s Moonshot Goals are Flexible Enough to be Realistic

    After a year of trying to understand the biology and politics of cancer, Vice President Joe Biden admits that he has a stronger grasp on the nuts and bolts of Washington than the evolutionary mysteries known collectively as cancer.

    Hosting the National Cancer Moonshot Summit at Howard University on June 29, Biden delivered a wide-ranging speech, even as his main initiatives remain what they have been from the start of his cancer odyssey:

  • Biden Announces FDA Center of Excellence

    Vice President Joe Biden announced the formation of the FDA Oncology Center of Excellence, which is intended to consolidate the agency’s cancer portfolio and streamline regulatory pathways for cancer-related drugs, biologics, and devices.

    Richard Pazdur, currently the director of the Office of Hematology and Oncology Products, will serve as acting director of the agency’s new cancer center.

    Biden’s June 29 announcement at the National Cancer Moonshot Summit in Washington, D.C. follows months of lobbying by oncology professional societies, advocacy and patient groups.

  • Conversation with The Cancer Letter

    Pazdur Named Acting Director of FDA’s New Cancer Center

    Richard Pazdur, currently the director of the FDA Office of Hematology and Oncology Products, will serve as acting director of the newly formed FDA Oncology Center of Excellence.

    The exact structure, budget and staffing for the program will be determined in an ongoing process, Pazdur said to The Cancer Letter.

    “Because I will be working to develop the structure of the OCE with input across all centers, it would be premature to speculate about what the ultimate structure of the OCE will be,” Pazdur said. “The framework of the OCE will evolve over time, so as not to disrupt the ongoing work in each center.”

  • Biden: What I Learned About Cancer

    A transcript of Biden’s speech at the National Cancer Moonshot Summit at Howard University.

  • In Brief

    • Haakon Ragde named 2016 Honorary Member of ASTRO
    • Steven Paul elected chairman of Foundation for the NIH
    • Stephen Burley named leader of cancer pharmacology research at Rutgers Cancer Institute of New Jersey
    • Firas Eladoumikdachi named program director at Rutgers Cancer Institute of New Jersey at Hamilton
    • Joel Katz received Spirit of Life Award from City of Hope
    • American Cancer Society plans to double research budget in five years
    • Research!American launches 2016 election blog
    • Mount Sinai and Valley Health System to form partnership
    • IBM Research to collaborate with Melanoma Institute Australia
    • Wistar Institute enters agreement with Christiana Care Graham Cancer Center
  • Drugs and Targets

    • FDA approves Epclusa for chronic hepatitis C
    • FDA grants fourth breakthrough designation to Imbruvica
    • FDA grants fast track designation to TK216 in Ewing sarcoma
    • Hetero launches generic bevacizumab in India
    • Novartis enters into agreement with Xencor
    • OmniSeq receives New York State CLEP approval

Copyright (c) 2017 The Cancer Letter Inc.